ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Mirion Medical Introduces Instadose®VUE Dosimeter at Radiological Society of North America (RSNA) Annual Meeting

Innovative Solutions for Diagnostic Imaging QA, Nuclear Medicine, & Medical Imaging Tables Also Featured for Mirion Medical at RSNA

Mirion (“we” or “the company”), announced today that it will debut the new Instadose®VUE personal dosimeter, from its Dosimetry Services brand, at the 2023 Radiological Society of North America (RSNA) Meeting starting Sunday in Chicago, Illinois. Mirion Dosimetry Services joins Sun Nuclear, Capintec, and Biodex medical imaging brands in the Mirion Medical booth (#6328) at RSNA, which will feature products and services for occupational dosimetry, diagnostic imaging QA, nuclear medicine, and medical imaging tables and accessories.

Introducing the InstadoseVUE Personal Dosimeter

The new Instadose®VUE advanced, wireless personal dosimeter offers a display screen for improved user engagement, insights, and compliance. Harnessing Bluetooth® Low Energy Technology, the InstadoseVUE dosimeter enables wearers to capture personalized dose reads on-demand, anytime and anywhere. With programmable calendar features, scheduling automatic dose reads ahead of time is easy, simplifying dose reporting and management even further.

Highlights for the Mirion Medical Booth

Other industry-leading solutions featured at the Mirion Medical booth include:

  • IQphan™ Phantom for comprehensive CT QA (Sun Nuclear)
  • RapidCHECK™ Analysis Software (Sun Nuclear)
  • Captus® 4000e Thyroid Uptake System (Capintec)
  • CRC® Dose Calibrators and Well Counters (Capintec)
  • Surgical C-Arm Table – 840 (Biodex)
  • Sound Pro™ Combination Table (Biodex)

Mirion Medical experts will be on hand to provide product insights and demonstrations.

ec² Software Solutions, Now Part of Mirion Medical

Earlier this month, Mirion Medical welcomed ec² Software Solutions, expanding the company’s Nuclear Medicine and Molecular Imaging Portfolio. Featured for ec² at RSNA in booth #2101, Numa® software provides innovative DICOM and HL7 workflow and communications solutions to meet the specific needs of nuclear medicine, nuclear cardiology, Radiopharmacies, PET and PET/CT departments.

"We are thrilled to welcome ec² Software Solutions to our medical family of solutions, further expanding and strengthening our commitment to leverage ionizing radiation to support innovation in healthcare. By adding to our portfolio through acquisitions and strengthening our proven technologies, as we’ve done with our new InstadoseVUE dosimeter, we continue to build on the depth and breadth of our medical portfolio,” said Thomas Logan, Mirion CEO.

RSNA attendees can gain insights on these products and more in Mirion Medical booth #6328 at RSNA.

About Mirion

Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,700 people and operates in 12 countries. Learn more at: mirion.com.

InstadoseVUE, IQphan, RapidCHECK, Captus, CRC, Sound Pro, Numa, Sun Nuclear, Capintec, Biodex and Mirion Dosimetry Services are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.